

NYRx Formulary Update: Pulmicort[®] Flexhaler

February 20, 2026

What Pharmacy Providers and Prescribers Need to Know

As of late 2025, H2-Pharma discontinued manufacturing of Pulmicort Flexhaler[®] (budesonide). A new distributor, Rubicon Holdings, has issued new NDCs replacing the previous manufacturer codes. Because Rubicon Holdings does not participate in the Medicaid Drug Rebate Program (MDRP), **these new NDCs are not covered by NYRx, the Medicaid Pharmacy Program.** Prior authorization is not available for this medication.

What Prescribers Need to Do

Prescribers should switch patients to an alternative preferred product. Preferred products typically do not require prior authorization when prescribed according to the FDA labeling. To review a list of preferred products, refer to the [NYRx Preferred Drug Quick List](#). If a preferred product is not clinically appropriate, prescribers should review details about prior authorization requirements in the [NYRx Preferred Drug List \(PDL\)](#). For a complete list of drugs covered by NYRx, refer to the [Medicaid Pharmacy List of Reimbursable Drugs](#).

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.